The patents correspond to the NCEs for the treatment of disorders associated with neurodegenerative diseases
Suven Life Sciences (Suven) has received product patents from Australia and Canada. The patents correspond to the New Chemical Entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases and are valid through 2032 and 2031 respectively.
The granted claims of the patent from Australia include the class of selective 5-HT4 compounds and the granted claims of the patent from Canada is through mechanism of action – H3 Inverse agonist and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia.
With these new patents, Suven has a total of 23 granted patents from Australia and 22 granted product patents from Canada. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II.